An interventional study of Novel Pulsed Field Ablation System and Radiofrequency Ablation Catheter in Paroxysmal Atrial Fibrillation, Pulsed Field Ablation and Catheter Ablation, sponsored by Tianjin Medical University General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Tianjin Medical University General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.
Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 131st largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 148 of the 182 other live ones, and was the 373rd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 20 · Phase 4 28
First in 2005; this study’s year is marked. 48 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 235 across the 256 interventional studies, 500 across the 121 observational. Of the 110 that completed or were terminated, 24 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 377 have an industry lead sponsor. The 10 most frequent:
Tianjin Medical University General Hospital is the lead sponsor of 75 studies on the registry; 31 are open to participants now.
Tianjin Medical University General Hospital has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
50 of the studies in Atrial Fibrillation with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06722196Phase 3Jilin Heart HospitalBiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery | 2027-01-15 |
| NCT06125925The First Affiliated Hospital with Nanjing Medical UniversityCatheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) | 2026-11 |
| NCT07139314Capital Medical UniversityTiming of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2 | 2026-11-30 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
Add all 50 to your calendar (.ics) → With an account.
Among the 377 studies in Atrial Fibrillation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective clinical study aiming to evaluate the clinical efficacy and safety of a novel domestic pulsed field ablation (PFA) system in the treatment of paroxysmal atrial fibrillation (PAF), and to specifically assess its protective effect on left atrial function.
Approximately 200-220 patients with paroxysmal atrial fibrillation are planned to be enrolled. Participants will be treated with the novel PFA system (YTL-PFA01) and a three-dimensional electroanatomical mapping system.
The primary objectives include:
Efficacy: Immediate pulmonary vein isolation success rate, and freedom from atrial arrhythmias (>30 seconds) at 12 months post-procedure.
Safety: Incidence of major complications (such as cardiac tamponade, stroke, pulmonary vein stenosis, phrenic nerve palsy).
Left Atrial Function: Dynamic changes in echocardiographic parameters (e.g., LAVI, LVEF, E/A, LASr/cd/ct) and serum biomarkers (e.g., troponin, BNP, inflammatory markers) at multiple time points before and after the procedure.
Patients will be followed up for 12 months to evaluate the long-term outcomes and quality of life improvement (EQ-5D-5L). The study duration is expected to be 36 months (October 2025 to September 2028).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be treated with the novel Pulsed Field Ablation system
Device: Novel Pulsed Field Ablation System
Patients will be treated with conventional radiofrequency catheter ablation.
Device: Radiofrequency Ablation Catheter
Use a novel PFA system (YTL-PFA01) and a three-dimensional electroanatomical mapping system to perform pulmonary vein isolation.
Use conventional radiofrequency ablation catheters to perform pulmonary vein isolation.
Freedom from atrial arrhythmia recurrence at 12 months
Percentage of participants free from documented atrial arrhythmias (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting \>30 seconds at 12 months post-ablation.
Time frame: 12 months post-procedure
Incidence of major procedure-related complications
Incidence of major adverse events related to the procedure, such as cardiac tamponade, thromboembolic events, vascular complications, pulmonary vein stenosis, and phrenic nerve injury.
Time frame: Within 12 months post-procedure
Change in left atrial volume index (LAVI)
Change from baseline in left atrial volume index (LAVI) at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in left ventricular ejection fraction (LVEF)
Change from baseline in left ventricular ejection fraction (LVEF) at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in mitral inflow E/A ratio
Change from baseline in E/A ratio at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in left atrial reservoir strain (LASr)
Change from baseline in LASr at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in tissue Doppler a'/e' ratio
Change from baseline in a'/e' ratio at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in left atrial conduit strain (LAScd)
Change from baseline in LAScd at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in left atrial contractile strain (LASct)
Change from baseline in LASct at each follow-up visit.
Time frame: Baseline to 12 months post-procedure
Change in quality of life score
Change from baseline in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) health-related quality of life questionnaire score. The scale consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). The minimum score for each dimension is 1 (no problems) and the maximum score is 5 (unable to/extreme problems), with a total score range of 5 to 25. Higher scores indicate a worse health-related quality of life outcome.
Time frame: Baseline to 12 months post-procedure
Change in myocardial injury markers (troponin)
Change from baseline in troponin at different time points.
Time frame: Baseline to 12 months post-procedure
Change in inflammatory markers (CRP)
Change from baseline in C-reactive protein (CRP) at different time points.
Time frame: From the initial assessment to 12 months after the procedure
Change in inflammatory markers (IL-6)
Change from baseline in interleukin-6 (IL-6) at different time points.
Time frame: Baseline to 12 months post-procedure
Change in fibrosis markers (Galectin-3)
Change from baseline in Galectin-3 at different time points.
Time frame: Baseline to 12 months post-procedure
Change in fibrosis markers (sST2)
Change from baseline in soluble ST2 (sST2) at different time points.
Time frame: Baseline to 12 months post-procedure
Plan to share: Yes
Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tianjin Medical University General Hospital